For the second time in two months, discordant pivotal trial results led to a negative US FDA advisory committee review of an inhaled ciprofloxacin formulation to treat non-cystic fibrosis bronchiectasis (NCFB).
In the case of Aradigm Corp.'s Linhaliq (ciprofloxacin dispersion for inhalation), however, some of the panelists suggested they could...





